This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. 3 H]-arachidonic acid release, prostaglandin E 2 (PGE 2 ) synthesis, cell cycle distribution, and apoptosis were determined. Results: Treatment of rat mesangial cells and mouse renal fibroblasts with NVP-231 decreased DNA synthesis, but not of agonist-stimulated arachidonic acid release or PGE 2 synthesis. Similarly, proliferation but not arachidonic acid release or PGE 2 synthesis was reduced in CERK knockout renal fibroblasts. The anti-proliferative effect of NVP-231 on mesangial cells was due to M phase arrest as determined using the mitosis markers phospho-histone H3, cdc2 and polo-like kinase-1, and induction of apoptosis. Moreover, loss of CerK sensitized cells towards stress-induced apoptosis. Conclusions: Our data demonstrate that CerK induces proliferation but not PGE 2 formation of renal mesangial cells and fibroblasts, and suggest that targeted CerK inhibition has potential for treating mesangioproliferative kidney diseases.
Germany; secondary horseradish peroxidase-coupled IgGs, Hyperfilm MP and enhanced chemiluminescence reagents were from GE Health Care Systems, Glattbrugg, Switzerland. Human recombinant IL-1β was from Cell Concept, Umkirch, Germany; TNF-α was a gift from Knoll AG, Ludwigshafen, Germany; PDGF-BB was kindly provided by Dr. Michael Pech, F.Hoffmann-La Roche Ltd., Basel, Switzerland; antibodies against glyceraldehyde 3-phosphate dehydrogenase (GAPDH), total histone H3, cleaved caspase-3, PARP-1, phospho-Tyr 15 -cdc2, total cdc2, phospho-Ser 133 -cyclin B1, total cyclin B1, phospho-Thr
210
-PLK1, and total PLK1 were obtained from Cell Signaling, Schwalbach, Germany; COX2 and β-actin were from Santa Cruz Biotechnology Inc., Heidelberg, Germany; phospho-Ser
10
-histone H3 was from EMD Millipore Corporation; ATP, TPA, ionomycin, forskolin, and NVP-231 were obtained from Sigma Aldrich Fine Chemicals, Buchs, Switzerland; all cell culture additives were from Invitrogen AG, Basel, Switzerland.
Cell culture and stimulation
Rat glomerular mesangial cells were isolated, characterized and cultured as described [16] . CerK deficient mice were kindly provided by Dr. Bornancin (Novartis Pharma AG, Basel) [17] . Mouse renal fibroblasts were isolated from wildtype BalbC mice or CerK deficient mice as described [18] and plated on collagen-coated plastic dishes. Rat cells were cultivated in RPMI medium supplemented with 10 % fetal bovine serum (FBS), 10 mM HEPES pH 7.4, 6 µg/ml bovine insulin, 5 µg/ml transferrin, 5 ng/ml sodium selenite, 100 units/ml penicillin, and 100 µg/ml streptomycin. Mouse cells were cultivated in the same medium but additionally supplemented with 1% non-essential amino acids and 45 µM β-mercaptoethanol. All cells were grown at 37 0 C in a humidified atmosphere containing 5 % CO 2 .
Cell homogenization and Western blot analysis
After treatment cells were washed with phosphate-buffered saline (PBS), scraped and homogenized in lysis buffer [19] and centrifuged for 10 min at 13'000 x g. The supernatant was taken for protein determination and 30 µg of protein was separated by SDS-PAGE, transferred to nitrocellulose membrane and immunostained using antibodies as indicated in the figure legends.
Determination of arachidonic acid release
Confluent cells in 24-well plates were labelled for 24 h with 1 µCi/ml of [ 3 H]-arachidonic acid in Dulbecco's modified Eagle medium (DMEM) containing 0.1 mg/ml of fatty acid-free bovine serum albumin (BSA). Cells were then washed three times with DMEM containing 1 mg/ml of BSA to remove all unincorporated arachidonic acid. Thereafter, cells were stimulated as indicated and the supernatant was taken for determination of released radioactivity.
Determination of DNA synthesis
To measure DNA synthesis in cells, the incorporation of [
Results

CerK inhibition does not abrogate agonist-induced arachidonic acid release or PGE 2 formation in renal mesangial cells
It was previously suggested that C1P is involved in cPLA 2 activation by directly binding and activating the enzyme [12] . To investigate this further, we measured the effect of CerK on cPLA 2 activation in rat renal mesangial cells using a novel potent catalytic inhibitor of CerK, NVP-231 [21] . This inhibitor demonstrated an in vitro IC 50 value for CerK of 12 nM [21] . NVP-231 competitively binds to the ceramide binding site of the enzyme, is highly cell-permeable and active under intracellular conditions [21] .
As a cellular activity assay of cPLA 2 , the release of [ ]-arachidonic acid-labelled cells were stimulated with either extracellular ATP or platelet-derived growth factor-BB (PDGF-BB), two well-known cellular cPLA 2 activators acting via the P2Y2 purinoceptor or PDGFRβ, respectively. Both agonists stimulated a pronounced arachidonic acid release after 30 min of stimulation ( Fig. 1A and  1B ). In the presence of NVP-231 no reduction of [ 3 H]-arachidonic acid release was observed upto 3 µM as the highest concentration tested.
Additional stimuli were also tested including serum, 12-O-tetradecanoylphorbol 13-acetate (TPA), ionomycin and the combination of TPA plus ionomycin. Whereas (Fig. 1C) , TPA alone or ionomycin alone exerted only marginal effects and only the combination of TPA plus ionomycin was synergistically active (Fig. 1D ). This confirms previous findings that phosphorylation of cPLA 2 by the protein kinase C/MAPK cascade alone, or increased intracellular Ca 2+ alone is not sufficient to fully activate cPLA 2 , and that only the combination of phosphorylation and increased Ca 2+ fully activates cPLA 2 [22, 23] . Again, in the presence of NVP-231 no reduction of either serum, TPA or ionomycin-induced arachidonic acid release was found. The combined stimulation with TPA plus ionomycin was even enhanced in the presence of NVP-231. Our data thus demonstrate that cPLA 2 activity induced by the various stimuli described above is not abrogated by CerK inhibition, a finding which questions the current hypothesis that C1P is necessary for cPLA 2 activity.
We also stimulated rat mesangial cells for 24 h with the pro-inflammatory cytokine IL-1β which is known to induce PGE 2 synthesis in these cells by combined induction and activation of cPLA 2 and group IIA sPLA 2 [24, 25] . Again, as shown in Fig. 2A , in the presence of low concentrations of NVP-231, PGE 2 formation was not reduced ( Fig. 2A) , whereas it was even enhanced at higher concentrations (1-5 µM). Analogous to the increased PGE 2 , COX2 protein expression was also upregulated (Fig. 2B ). Increased PGE 2 synthesis (Fig. 2C ) was also seen when cells were exposed to IL-1β in the presence of increasing concentrations of C 6 -ceramide suggesting that ceramide, which is expected to accumulate upon CerK inhibition, is responsible for the increased PGE 2 formation.
We next investigated what effect the complete genetic knockout of CerK has on arachidonic acid release and PGE 2 formation in mouse renal fibroblasts isolated from CerK (-/-) mice and control littermates (Wt). As shown in Fig. 3A , CerK knockout had no effect on the various agonists-triggered arachidonic acid release including TPA, ionomycin, the combination of TPA plus ionomycin, ATP and serum. Also, no difference in IL-1β-stimulated PGE 2 synthesis was observed in CerK (-/-) cells (Fig. 3B) . Altogether, our data do not confirm previous findings that CerK is positively involved in cPLA 2 activation and subsequent PGE 2 formation, but rather suggest the ability of the substrate ceramide to stimulate arachidonic acid release and promote COX-2 induction and subsequent PGE 2 formation. 
Inhibition of CerK decreases proliferation of renal mesangial cells and fibroblasts
A major biological function attributed to CerK is stimulation of cell proliferation [11] . Since mesangial cell proliferation is an important hallmark of many forms of chronic H]-thymidine incorporation. To this end, quiescent rat renal mesangial cells were stimulated with two well-known mitogens, i.e. extracellular ATP and PDGF-BB. As shown in Fig. 4A , ATP stimulated DNA synthesis already after 24 h. In the presence of NVP-231, this effect was dose-dependently decreased and resulted in almost complete inhibition at a dose of 3 µM NVP-231. PDGF-BB was a weaker mitogen for which 48 h of stimulation was required to increase DNA synthesis (Fig. 4B) . Again, this effect was dose-dependently decreased by NVP-231 (Fig. 4B) .
Similar to rat renal mesangial cells, a dose-dependent anti-proliferative effect of NVP-231 was also observed in mouse renal fibroblasts (Fig. 5A) . Furthermore, we found that the Fig. 7 . Effect of NVP-231 on phospho-histone H3, cdc2, cyclin B1 and PLK1 expression in rat mesangial cells. Rat mesangial cells were incubated for 24 h in growth medium in the absence or presence of the indicated concentrations (in µM) of NVP-231. Thereafter, cell lysates were prepared and proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes and subjected to Western blot analysis using antibodies against phospho-histone H3 (A), total histone H3 (A), phospho-Tyr 15 -cdc2 (A), total cdc2 (A), phosphocyclin B1 (A), total cyclin B1 (A), β-actin (A), phospho-PLK1 (B), and total PLK1 (B). A representative blot from two independent experiments performed in duplicates is shown. Fig. 8 . Effect of NVP-231 on PARP-1 cleavage in rat mesangial cells. Rat mesangial cells were treated for 24h with either vehicle (Co) or the indicated concentrations of NVP-231. Protein lysates were prepared and samples were separated by SDS-PAGE, transfer to nitrocellulose and subjected to Western blot analysis using antibodies against PARP-1 (upper panel) or GAPDH (lower panel). A representative blot from two independent experiments performed in duplicates is shown.
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Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry proliferation rate of CerK (-/-) fibroblasts detected over 6 days in culture was significantly lower compared to wildtype fibroblasts (Fig. 5B) . We next investigated whether CerK inhibition and decreased proliferation was associated with altered cell cycle distribution. To this end, rat mesangial cells were treated for 24 h with NVP-231 and the DNA content was determined. Strikingly, as shown in Fig. 6 , upon NVP-231 treatment, the number of cells in G1 (2N DNA content) and S phase (2N>4N) decreased and cells accumulated in G2/M (4N DNA content). At the same time, also the number of cells with fragmented DNA (sub G1 peak) and of polyploid cells with a 8N DNA content increased (Fig. 6C) .
To more specifically investigate whether cells accumulated at the G2/M boundary or were arrested in the M phase, lysates of NVP-231-treated cells were subjected to Western blot analysis and stained for cell cycle markers relevant for M phase regulation. As shown in Fig. 7A , the level of the mitosis marker phospho-histone H3 increased dose-dependently upon NVP-231 treatment indicating that cells were mainly arrested in M phase. The amount of total histone H3 remained unchanged (Fig. 7A) . Furthermore, we determined the level of cdc2 (CDK1) as a major regulator of G2-M transition and execution of mitosis [26, 27] . Cdc2 interacts wih cyclin B1 in a complex which is kept in an inactive state by Tyr 15 phosphorylation of cdc2. At the G2/M boundary, cdc2 is dephosphorylated and thereby activated to promote mitotic entry. Here, we found that cdc2 Tyr 15 phosphorylation was decreased upon NVP-231 treatment which further suggests that cells entered mitosis (Fig. 7A) . No change of cyclin B1 was seen neither on the level of phosphorylation nor total protein expression (Fig. 7A) . However, we found that treatment with NVP-231 also increased the phosphorylation and thus activation of polo-like kinase 1 (PLK1) (Fig. 7B) , a kinase regulating mitosis entry and [28] . Cells remaining in the sub G1 phase upon NVP-231 treatment underwent classical apoptosis as further confirmed by increased poly-(ADP-ribose)-polymerase-1 (PARP-1) cleavage [29] shown in Fig. 8 .
To investigate whether knockout of CerK in renal fibroblasts also facilitated apoptosis, DNA fragmentation detected by ELISA was measured in the presence of either staurosporine or TNFα/cycloheximide, two well-known inducers of apoptosis. As expected, both treatments induced DNA fragmentation (Fig. 9A and B) and this effect was significantly increased in CerK (-/-) fibroblasts (Fig. 9A and B) . Concomitantly, cleavage of caspase-3 and PARP-1 was increased compared to wildtype cells (Fig. 9C and D) .
Finally, to verify that in rat mesangial cells, CerK inhibition by NVP-231 results in the accumulation of cellular ceramide, the main ceramide subspecies C 16 -ceramide, and sphingosine for comparison, were quantified by mass spectrometry. As shown in Fig. 10 , C 16 -ceramide indeed dose-dependently increased from basal 18 ± 1.5 ng/ 10 6 cells to 39 ± 3.1 ng/ 10 6 cells upon treatment with 10 µM NVP-231, whereas sphingosine levels were not significantly changed.
Discussion
To date, the cellular function of CerK is still a matter of debate. Various studies demonstrated that CerK is an essential enzyme to produce C1P which, in turn, directly binds to and activates cPLA 2 resulting in the synthesis of pro-inflammatory PGE 2 . These data unveil a key role for CerK in inflammation and suggest CerK targeting as a treatment modality for inflammatory diseases [30, 31] . However, data from CerK gene deficient mice do not support this hypothesis, since the loss of CerK did not ameliorate disease symptoms in inflammationrelated disease models such as arthritis, peritonitis, thrombocytopenic purpura, and active or passive cutaneous anaphylaxis models [17] . Moreover, in a mouse model of fulminant pneumonia, CerK deficient mice showed even more severe symptoms and increased mortality. The lack of effect of CerK gene knockout in most of these experimental disease models may be due to systemic compensatory mechanisms to restore C1P homeostasis. Conflicting data were also reported from cells isolated from CerK (-/-) mice. On the one hand, Graf et al. [17] found no change of agonist-induced arachidonic acid release and PGE 2 formation in CerK (-/-) peritoneal macrophages compared to wildtype macrophages which fits well to our data. On the other hand, using mouse embryonic fibroblasts and bone marrow-derived macrophages from the same CerK (-/-) mouse strain, Mietla et al. [32] reported considerably decreased formation of arachidonic acid and various prostaglandin subspecies measured by mass spectrometry. The reason for this discrepancy is unclear. Similarly, as shown in RAG1-deficient mice, the additional depletion of CerK resulted in lower basal PGE 2 levels in bronchoalveolar lavage fluid [33] . However, upon ovalbumin stimulation as a model of experimentally-induced asthma, the induction of PGE 2 synthesis was manifold higher in 
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CerK (-/-) compared to CerK (+/+) mice, whereas the total amount of PGE 2 reached by ovalbumine stimulation was still identical in the two mouse strains as was the severity of disease symptoms [33] . An alternative approach to overcome potential compensatory mechanisms of CerK gene knockout is the use of catalytic CerK inhibitors. Such an inhibitor, NVP-231, has been developed recently which demonstrated an in vitro IC 50 value for CerK of 12 nM [21] . The inhibitor proved to be highly cell-permeable and active under intracellular conditions [21] . Using NVP-231 in renal mesangial cells, we could clearly demonstrate that inhibition of CerK activity does not decrease either arachidonic acid release or PGE 2 formation in renal mesangial cells. Rather, we found an increase of PGE 2 ( Fig. 2A) as a consequence of upregulated COX2 protein (Fig. 2B) . This finding may be mechanistically explained by an increase of intracellular ceramide upon CerK inhibition (Fig. 10) .
In fact, ceramide has been discussed as a pro-inflammatory lipid for many years. Mechanistically, ceramide was on the one hand shown to activate cPLA 2 [34] [35] [36] and also to enhance the expression of sPLA 2 [37] and COX2 [38] [39] [40] in various cell types, including mesangial cells and fibroblasts. Furthermore, in several inflammation-related disease models, ceramide was shown to contribute to an inflammatory phenotype such as in cystic fibrosis [41] , pulmonary emphysema [42] , and other acute and chronic lung injuries [43] . Whatever the pro-inflammatory mechanism of ceramide is, our data strongly suggest that CerK is not a suitable target for the treatment of inflammation and that its inhibition may result in the opposite effect i.e. acceleration of PGE 2 formation, which worsens symptoms even further.
Here we found that inhibition of CerK in renal mesangial cells using NVP-231 reduced proliferation and sensitized cells to stress-induced apoptosis.
A role for CerK in the regulation of apoptosis was first proposed by Liang et al. [44] who showed that in Arabidopsis, mutation of the plant homolog of CerK, also denoted "accelerated cell death 5" (acd5), not only led to an accumulation of ceramides, but also increased calcium mobilization and cell death upon pathogen infection [44, 45] . Similarly, downregulation of CerK using RNA interference was shown to inhibit proliferation and enhance apoptosis also in human A549 lung adenocarcinoma cells [46] . Apart from these preclinical findings, evidence for a key role of CerK in tumor progression was reported by Ruckhäberle et al. [47] , who demonstrated that high CerK expression in tumor tissues correlated with a worse prognosis in patients with estrogen receptor-negative breast cancer. Moreover, recent data also suggest that the CerK protein is upregulated as a hormetic response of hepatoma cells exposed to UV irradiation to evade apoptosis, which could be counteracted by CerK silencing [48] . Based on this observation, pharmacological inhibition of CerK was suggested as a new concept in hepatoma therapy. The anti-proliferative and pro-apoptotic potential of CerK targeting is also corroborated by our data from CerK (-/-) fibroblasts demonstrating that the loss of CerK facilitates apoptosis induced by stress factors such as staurosporine or TNFα combined with cycloheximide (Fig. 9) .
Further evidence that CerK targeting to decrease cell proliferation and survival may have therapeutic potential also derived from studies were CerK activity was affected indirectly. For instance, the anti-proliferative effect of vitamin D 3 on neuroblastoma cells was shown to involve the downregulation of CerK and C1P by vitamin D 3 [49] , and CerK downregulation was also involved in all-trans retinoic acid (ATRA)-induced differentiation of neuroblastoma cells [50] . In mouse keratinocytes, it was correspondingly shown that the peroxisome proliferator-activated receptor β (PPARβ) promoted cell survival, which was dependent on PPARβ-mediated upregulation of CerK [51] . Consequently, in CerK deficient mice, PPARβ-mediated keratinocyte survival was strongly decreased [51] . These findings together with our data strongly support a key role for CerK in cell proliferation and survival.
Here, we report that in mesangial cells inhibition of CerK using NVP-231 induced M phase arrest and subsequent apoptosis. M phase arrest was confirmed by various parameters, including reduced Tyr 15 phosphorylation of cdc2, reflecting enhanced cdc2 activity and mitotic entry, and enhanced phospho-histone H3 as a marker of mitosis. Furthermore,
